HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Private Label OTC Giant Stretches For Switch Help

Perrigo Will Pay $2.1Bn In Cash Deal For HRA Pharma

Executive Summary

HRA brings needed expertise in OTC switches to Perrigo, which regularly is first to launch generic equivalents for brand switches but its name hasn’t been linked to submitting proposals for making additional drug ingredients available OTC.

You may also be interested in...



HRA Brings Mederma Scar-Care Brand To UK

British consumers can now buy three Mederma scar-care products in the UK via Amazon and Superdrug thanks to a recent launch by France's HRA Pharma. 

Preparing For Expansion: Perrigo Sets $500M Private Offering, Bausch + Lomb IPO Details Filed

Perrigo intends to use net proceeds from $500m private offering along with cash on hand and funds from previous credit facilities to finance acquisition of HRA Pharma. Bausch Health reduces debt by $200m as it prepares to target proceeds from planned Bausch + Lomb IPO also to paying down debt.

Perrigo Feels Chill From Q3 Results Due To ‘Unfulfilled’ Demand On Supply Chain Disruptions

“Unfulfilled orders' from retailers and other product distributors due to supply chain disruptions slowed revenues, net income and earnings per share during the quarter and prompted lower full-year guidance while also leaving analysts with doubts.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS151737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel